Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative care. Recently an international panel of expert have succeeded to elaborate dedicated recommendations for cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) in a two-part series of guidelines based on expert consensus (Hübner et al., EJSO, 2020). The aim of this prospective validation study was therefore to study acceptance, feasibility and clinical results of these guidelines in clinical practice. Hypothesis of the study: Introduction of ERAS® guidelines is feasible and safe. Increasing compliance with ERAS® guidelines (after implementation) will improve recovery and early clinical outcomes of patients undergoing CRS/HIPEC.
The study includes two succesive phases interrupted by a stage to implement ERAS® guidelines.
Study Type
OBSERVATIONAL
Enrollment
288
Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
University of Texas Southwestern Medical Center
Dallas, Texas, United States
RECRUITINGUniversity of Calgary, Arnie Charbonneau Cancer Institute
Calgary, Alberta, Canada
RECRUITINGLausanne University Hospital
Lausanne, Switzerland
RECRUITINGCompliance of ERAS® guidelines
Post-ERAS® implementation phase: compliance rate towards the relevant core items from ERAS guidelines
Time frame: 3 months
Acceptance and feasibility of ERAS® guidelines
Pre-ERAS® phase (current clinical practice): current compliance rate towards the ERAS guidelines
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.